Inactive Instrument

ITUS Corp Share Price OTC Bulletin Board

Equities

ITUS

US45069V1044

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for ITUS Corp
Sales 2024 * - Sales 2025 * - Capitalization 95.7M 7.64B
Net income 2024 * -14M -1.12B Net income 2025 * -15M -1.2B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-6.82 x
P/E ratio 2025 *
-6.67 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.09%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 59 31/10/12
Director of Finance/CFO 57 31/10/16
Corporate Officer/Principal 69 06/09/21
Members of the board TitleAgeSince
Director/Board Member 79 30/06/99
Chief Executive Officer 59 31/10/12
Director/Board Member 63 22/10/19
More insiders
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.
More about the company